Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IndegeneNSE:INDGN -0.01%49 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates NSE:INDGN with a GF Score™ of 49/100. The stock has 5 warning signs investors should review. Among 608 Healthcare Providers & Services companies, Indegene ranks worse than 164473.52% on this metric.
The historical rank and industry rank for Indegene's Days Payable or its related term are showing as below:
NSE:INDGN's Days Payable is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 57.32 * Ranked among companies with meaningful Days Payable only.
Indegene's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Indegene Days Payable Related Terms
Indegene Days Payable Historical Data
* Premium members only.
The historical data trend for Indegene's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDGN vs VEEV, BTSG, TEM: Days Payable Comparison
For the Health Information Services subindustry, Indegene's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indegene Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Indegene's Days Payable distribution charts can be found below:
* The bar in red indicates where Indegene's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Indegene's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indegene (NSE:INDGN) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Indegene and its competitors. According to the industry distribution chart, Indegene ranks #999999 out of 608 companies in the Healthcare Providers & Services industry.
Is Indegene's Days Payable too high?
Indegene's current Days Payable is 0.00. Based on the distribution chart, Indegene ranks #999999 out of 608 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Indegene has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Indegene's Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Indegene ranks #999999 out of 608 companies for Days Payable. This places Indegene in the lower half of its industry. The industry median Days Payable is 57.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 57.32, based on 608 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Indegene and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 57.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indegene's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indegene stock overvalued right now?
Indegene (NSE:INDGN) has a current Days Payable of 0.00. The current Days Payable is 0.00. Indegene's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Indegene (NSE:INDGN), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical device companies. It assists them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations for life sciences companies. The company's segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment. The company has a presence in India, Europe, and North America, with the majority of revenue coming from North America.
49GF Score
Get the complete analysis for NSE:INDGN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDGN has been successfully added to your 
